TTY Biopharm Company (4105) Fair Value & Analysis
Healthcare · TW · Market cap 19.4B TWD
Fair value as of: Jul 21, 2026
From 26 valuation models · updated 19 days ago
Share price −0.9% over the past month.
A strong business, screening 44% undervalued on our models.
What matters now
- The rarer combination: high quality (79/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case (83.13 TWD). The market is more pessimistic than our downside scenario.
- A fairly wide model range (83.13 TWD to 164.21 TWD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 58.48 TWD – 86.30 TWD · fair‑value band 83.13 TWD – 164.21 TWD · the 76.50 TWD price screens below the 109.90 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
TTY Biopharm Company (4105) currently trades at 76.50 TWD, while our model-based Fair Value estimate is 109.90 TWD, implying the stock looks roughly 43.7% undervalued today. The Quality Score stands at 79/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, TTY Biopharm Company generated revenue of 6.5B TWD at a net margin of 24.7%. Revenue grew 4.2% year over year. It earns a return on equity of 23.9%. The balance sheet holds a net cash position of 706M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 83.13 TWD (bear case) to 164.21 TWD (bull case); at 76.50 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 12% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 44%, 4105 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (130.56 TWD) versus Asset-Based (19.50 TWD). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 76 · Market factors (momentum, volatility) 56
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally.
Full company description
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers oncology drugs for the treatment of anticancer and adjunctive therapies under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Yondelis, Pemazyre, Pulmivex, Xpovio, Minjuvi, and Fustron names. The company also provides anti-infective drugs and anesthetics to treat second-line antimicrobial agents, influenza, and anesthetics under the Brosym, Bobimixyn, Colimycin, Cubicin, Lipo-AB, Flusine, Maxtam, Metacin, Flucelvax, Fluad, and Byfavo names; and healthcare products for the treatment of gastrointestinal health, bone health, and metabolic regulation under the Algitab, Alginos, Bio-Cal Plus, Sulfin names. In addition, it offers contract development and manufacturing (CDMO) services. The company was incorporated in 1960 and is headquartered in Taipei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
TTY Biopharm Company reported revenue of 6.5B TWD in FY2025 versus 4.5B TWD in FY2021, a compound +9.2%/yr. Reported net income was 1.6B TWD in FY2025, compounding +17.0%/yr from FY2021.
Watch 4105: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 626 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare TTY Biopharm Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is TTY Biopharm Company (4105) overvalued or undervalued?
What is the fair value of 4105?
What is the quality score of 4105?
What is the revenue of TTY Biopharm Company (4105)?
What is the net profit margin of 4105?
Does TTY Biopharm Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track TTY Biopharm Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.